X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
female (15) 15
male (15) 15
antineoplastic agents - therapeutic use (14) 14
bortezomib (13) 13
middle aged (13) 13
aged (12) 12
pyrazines - therapeutic use (11) 11
treatment outcome (11) 11
boronic acids - therapeutic use (10) 10
index medicus (10) 10
oncology (9) 9
recurrence (9) 9
adult (8) 8
hematology (8) 8
multiple myeloma - drug therapy (8) 8
aged, 80 and over (6) 6
boronic acids - adverse effects (6) 6
multiple myeloma - mortality (6) 6
pyrazines - adverse effects (6) 6
care and treatment (5) 5
thalidomide (5) 5
animals (4) 4
antineoplastic agents - adverse effects (4) 4
chemotherapy (4) 4
dexamethasone (4) 4
dexamethasone - therapeutic use (4) 4
high-dose therapy (4) 4
multiple myeloma (4) 4
non-hodgkins-lymphoma (4) 4
survival rate (4) 4
apoptosis (3) 3
boronic acids - administration & dosage (3) 3
c-raf kinase (3) 3
cancer (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
clinical trials (3) 3
dexamethasone - administration & dosage (3) 3
follow-up studies (3) 3
lung neoplasms - drug therapy (3) 3
medicine, general & internal (3) 3
mice (3) 3
protease inhibitors - therapeutic use (3) 3
proteasome (3) 3
pyrazines - administration & dosage (3) 3
receptor protein-tyrosine kinases - genetics (3) 3
refractory myeloma (3) 3
research (3) 3
tumors (3) 3
abridged index medicus (2) 2
angiogenesis (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
antisense (2) 2
biomedicine (2) 2
cell line, tumor (2) 2
chemistry (2) 2
combination (2) 2
crizotinib (2) 2
disease progression (2) 2
dosage and administration (2) 2
free survival (2) 2
gene rearrangement (2) 2
human necessities (2) 2
hygiene (2) 2
inhibitor (2) 2
lung neoplasms - genetics (2) 2
lymphoma (2) 2
lymphoma, mantle-cell - drug therapy (2) 2
mantle cell lymphoma (2) 2
maximum tolerated dose (2) 2
medical or veterinary science (2) 2
metallurgy (2) 2
metastasis (2) 2
molecular mechanisms (2) 2
multicenter (2) 2
multiple-myeloma (2) 2
multiple-myeloma cells (2) 2
neoplasms - drug therapy (2) 2
nf-kappa-b (2) 2
organic chemistry (2) 2
peptides (2) 2
pharmaceutical industry (2) 2
pharmacology/toxicology (2) 2
preparations for medical, dental, or toilet purposes (2) 2
protease inhibitors - administration & dosage (2) 2
protease inhibitors - adverse effects (2) 2
proteasome inhibitor bortezomib (2) 2
proteasome inhibitor ps-341 (2) 2
proteasome inhibitors (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
pyrazines - pharmacology (2) 2
pyrimidines - administration & dosage (2) 2
pyrimidines - adverse effects (2) 2
receptor protein-tyrosine kinases - antagonists & inhibitors (2) 2
recombination, genetic (2) 2
respiratory system (2) 2
rituximab (2) 2
specific therapeutic activity of chemical compounds ormedicinal preparations (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4783 - 4783
Abstract Background: Systemic mastocytosis (SM) is a rare mast cell disorder associated with a range of debilitating symptoms and a shortage of effective... 
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2013, Volume 110, Issue 50, pp. 20224 - 20229
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2005, Volume 352, Issue 24, pp. 2487 - 2498
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2009, Volume 144, Issue 6, pp. 895 - 903
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2008, Volume 143, Issue 1, pp. 46 - 53
Journal Article
Cancer Research, ISSN 0008-5472, 10/1998, Volume 58, Issue 19, pp. 4211 - 4216
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2013, Volume 110, Issue 50, p. 20224
  Wnt signaling is one of the key oncogenic pathways in multiple cancers, and targeting this pathway is an attractive therapeutic approach. However,... 
Molecules | Phosphorylation | Membranes | Inhibitor drugs | Breast cancer | Gene expression
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2006, Volume 108, Issue 11, pp. 2759 - 2759
Abstract Phase II studies have established the efficacy of single agent Bor in patients with B-cell non-Hodgkin’s Lymphoma (NHL). We sought to determine the... 
Journal Article